General Facts about Gene Therapy:

#LentiGlobin and #Exa-cel studies

#Casgevy #Lyfgenia #GeneTherapy #CRISPR #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials
@ash.edu.hematology.org @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@bsochaem.bsky.social

SCD and Gene Therapy:

Additional facts about the LentiGlobin Study

@asgct.bsky.social @ash.edu.hematology.org @ash.hematology.org @cuhemeonc.bsky.social @bsochaem.bsky.social #Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #MedicalEducation #InternalMedicine

SCD and Gene Therapy:

Additional facts about the LentiGlobin Study

@ash.hematology.org @asgct.bsky.social @ash.edu.hematology.org
#Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy

Why might anemia persist in a patient treated with Lyfgenia despite elimination of VOCs?

See the answer and explanation on the next slide!

#Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy

Facts about #SickleCellDisease and #GeneTherapy

Study Focus: #LentiGlobin

The HGB-206 clinical trial refined the treatment process, including transfusion regimens, busulfan conditioning, and manufacturing methods, leading to improved and consistent outcomes for patients with sickle cell disease.